Skip to main content

Temporary codes (Q codes)

95 Part B drug codes in this range (85 with an October 2026 ASP payment limit, 10 paid under OPPS without one), practitioner MUE values, NCCI column-2 exposure and the number of Medicare coverage articles that list each code. Open a code for its NDC billing-unit conversions, every MUE setting and the denial codes to expect.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Most searched codes in this range

Monthly US Google searches for the bare code (Google Ads, October 2026) show which entries coders and billers look up most; demand is one input to the index decision for each page and to which pages the hubs link first.

Temporary codes (Q codes): codes with the most Google searches
CodeDescriptionPayment limitSearches / month
Q9967Locm 300-399mg/ml iodine,1ml$0.1861,000
Q5136Inj. denosumab-bbdz, 1 mg$26.991880
Q0138Ferumoxytol, non-esrd$0.331720
Q5103Injection, inflectra$28.456720
Q5111Injection, udenyca 0.5 mg$128.967720
Q5115Inj truxima 10 mg$35.988720
Q5106Inj retacrit non-esrd use$8.171590
Q5108Injection, fulphila$55.964590
Q5107Inj mvasi 10 mg$28.294480
Q5119Inj ruxience, 10 mg$5.792590

Codes in this range

85 of the 95 codes carry a published October 2026 ASP payment limit, 10 show their OPPS rate instead; the remaining codes are priced by contractors or carry a limit of zero in the file. The table lists the 81 codes whose reference pages are indexed; the other 14 follow as a list.

Part B drug codes in Temporary codes (Q codes) with an indexed reference page
CodeDescriptorUnitLimitMUECol-2 pairsArticles
Q0138Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)1 MG$0.331510——
Q0162Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen1 MG$0.0160——
Q0166Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen1 MG$0.7740——
Q0167Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen2.5 MG$2.0920——
Q0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg4500 MG$7,615.201——
Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg1 MG$4.92———
Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg1 MG$7.5691600——
Q2009Injection, fosphenytoin, 50 mg phenytoin equivalent50 MG PE/ML$1.552 OPPS100——
Q2026Injection, radiesse, 0.1 ml0.1 ml$349.19 OPPS30—yes
Q2028Injection, sculptra, 0.5 mg0.5 mg$2.16 OPPS1470—yes
Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusionPer infusion (minimum 50 million cells)$55,663.13111yes
Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg10 mg$298.74 OPPS10——
Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg10 MG$97.82314——
Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dosePER THERAPEUTIC DOSE$813,967.3751——
Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusionPer Therapeutic Dose$293,725.7021——
Q4081Injection, epoetin alfa, 100 units (for esrd on dialysis)100 UNITS$0.667100—yes
Q5098Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg1 MG$9.27520——
Q5099Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg1 MG$2.89520——
Q5100Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg1 MG$3.08520——
Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram1 MCG$0.3381500—yes
Q5103Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg10 MG$28.456150—yes
Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units100 UNITS$0.817100—yes
Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units1000 UNITS$8.17160—yes
Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg10 MG$28.294230—yes
Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg0.5 MG$55.96412—yes
Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram1 MCG$0.3291500—yes
Q5111Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg0.5 MG$128.96712—yes
Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg10 MG$32.791120——
Q5113Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg10 MG$55.295120——
Q5114Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg10 MG$29.507120——
Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mg10 MG$35.988150—yes
Q5116Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg10 MG$11.271120——
Q5117Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg10 MG$63.871120——
Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg10 MG$25.939230—yes
Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg0.5 MG$302.24712—yes
Q5121Injection, infliximab-axxq, biosimilar, (avsola), 10 mg10 MG$34.686150—yes
Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg0.5 MG$141.28912—yes
Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg10 MG$21.083150—yes
Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg0.1 MG$249.49310—yes
Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram1 MCG$0.3081800—yes
Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg10 MG$79.982230—yes
Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg0.5 MG$163.94812—yes
Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg0.1 MG$81.1310—yes
Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg10 MG$21.139230—yes
Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg0.5 MG$94.29212—yes
Q5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg1 MG$4.7061200——
Q5134Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg1 MG$24.397300——
Q5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg1 MG$4.371200——
Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg1 MG$26.991120—yes
Q5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg1 MG$2.273520——
Q5146Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg10 MG$30.255120——
Q5147Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg1 MG$763.3764—yes
Q5148Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram1 MCG$1.0261500—yes
Q5151Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg2 MG$31.547600—yes
Q5152Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg2 MG$40.412600—yes
Q5154Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg5 mg$46.61 OPPS——yes
Q5156Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg1 MG$3.098———
Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg1 MG$24.002——yes
Q5158Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg1 MG$28.702——yes
Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg10 MG$82.139230—yes
Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg1 MG$27.509———
Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg1 MG$15.336——yes
Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg1 mg$29.72 OPPS——yes
Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg1 MG$7.681——yes
Q5168Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg0.1 MG$26.384——yes
Q5169Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg0.5 MG$519.481——yes
Q9950Injection, sulfur hexafluoride lipid microspheres, per ml1 ML$18.0525—yes
Q9956Injection, octafluoropropane microspheres, per ml1 ML$40.3239—yes
Q9958High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml1 ML$0.083004—
Q9961High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml1 ML$0.2052002—
Q9963High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml1 ML$0.219240——
Q9965Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml1 ML$1.7872507—
Q9966Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml1 ML$0.4212506—
Q9967Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml1 ML$0.1863005—
Q9968Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg1 MG$8.541 OPPS200——
Q9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesup to 5 millicuries$1,944.01 OPPS1——
Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuriesPER STUDY DOSE, UPTO 8 mCi$1,584.67 OPPS1——
Q9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mgLess than or equal to 100 MG$2,060.1321——
Q9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg1 MG$8.591520——
Q9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg1 MG$10.48520——
Q9999Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg1 MG$13.246520——
Show the other 14 codes on this page (pages not yet in search results)
  • Q0139 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) · limit $0.331
  • Q0234 Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg · limit $6.327
  • Q0238 Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg · limit $5.581
  • Q2041 Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $577,943.258
  • Q2042 Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $626,315.834
  • Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $532,352.741
  • Q2054 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $589,846.771
  • Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $575,850.465
  • Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose · limit $594,112.255
  • Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg · limit $25.649
  • Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg · limit $5.792
  • Q5172 Injection, filgrastim-laha (filkri), biosimilar, 1 microgram · OPPS $0.74
  • Q9957 Injection, perflutren lipid microspheres, per ml · limit $40.323
  • Q9992 Injection, buprenorphine extended-release (sublocade), greater than 100 mg · limit $2,060.132

How to read this table

The limit is the Medicare Part B payment allowance per billing unit for the quarter shown, not per dose: multiply it by the units that the administered quantity divided by the descriptor unit produces. Codes marked OPPS have no ASP limit and show the hospital outpatient rate per unit instead. The MUE column is the practitioner-setting Medically Unlikely Edit, the maximum units CMS expects on one date of service; facility and DME limits can differ and appear on each code page. Column-2 pairs counts the active NCCI procedure-to-procedure edits in which the code is the bundled component, and Articles marks codes that at least one Medicare Administrative Contractor lists in a current Billing and Coding Article with covered diagnosis codes. Codes without a published limit are contractor-priced or carry a zero limit in the CMS file.

For teams evaluating QuickIntell software

Evaluate software for HCPCS coding workflows

Evaluating a recurring coding workflow? Review QuickCode for qualified coder review, documentation clarification and the billing handoff. Use your unit, modifier and edit questions to confirm the supported scope; a published CMS table does not establish an automated claim check.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

How many codes are in temporary codes (q codes)?

95 Part B drug codes in this range: 85 carry an ASP payment limit in the October 2026 file and 10 are paid separately under OPPS without an ASP limit; 81 have enough joined CMS data (MUE, NCCI, OPPS, ASC or coverage) to be published as full reference pages.

Which payers use these payment limits?

Medicare Part B contractors apply the ASP limits directly. Medicaid programs and commercial payers publish their own fee schedules, which often reference ASP but at different percentages.

Why do some codes show no MUE?

CMS withholds some MUE values as confidential and applies them without publication; others have no unit limit. A code with no published MUE can still deny for units when the quantity is implausible for the dose.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Operational reference compiled from CMS publications. Payment limits are Medicare national amounts; other payers differ. CPT codes appear as numbers only. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.